Cerebrolysin

Cerebrolysin is a multi-modal neuropeptide medication produced by the biotechnological refinement of purified porcine (pig) brain proteins. It is composed of low-molecular-weight peptides and free amino acids that are small enough to cross the blood-brain barrier (BBB). Unlike many single-target drugs, Cerebrolysin contains a complex mixture of factors that mimic the activity of endogenous neurotrophic factors—natural substances in the body that promote the growth and survival of neurons. It is clinically utilized primarily in Europe and Asia for the treatment of ischemic and hemorrhagic stroke, traumatic brain injury (TBI), and various forms of dementia, including Alzheimer’s disease and vascular dementia.

Cerebrolysin works through a neurotrophic and neuroprotective multi-target approach:

• Neuroprotection: It protects neurons from damage caused by the 'ischemic cascade'—the series of toxic events (like glutamate excitotoxicity and free radical formation) that occur after a stroke or head injury.
• Neuroregeneration: It stimulates the Sonic Hedgehog (Shh) signaling pathway, which is critical for neurogenesis (the creation of new neurons) and the repair of neural circuits.
• Neuroplasticity: It enhances synaptic plasticity and dendrite arborization, effectively helping the brain 'rewire' itself to regain lost functions.
• Neurotrophic Mimicry: The peptides in Cerebrolysin mimic the actions of BDNF (Brain-Derived Neurotrophic Factor), GDNF, and NGF, which are vital for maintaining the structural integrity of the brain.
• Anti-inflammatory Effects: It has been shown to reduce neuroinflammation by modulating microglial activity and decreasing the production of pro-inflammatory cytokines.

Based on clinical trials such as the CARS (Cerebrolysin and Recovery After Stroke) and CAPTAIN (Cerebrolysin in TBI) studies, recommendations for use include:

• Stroke Recovery: Standard protocol often involves 20-50 mL daily via slow intravenous (IV) infusion for 10-21 days, ideally initiated within 72 hours of the event to maximize neurological recovery (Ziganshina et al., 2023).
• Dementia & Cognitive Decline: For Alzheimer's or vascular dementia, a common cycle is 10-30 mL daily for 5 consecutive days per week, over a 4-week period. This cycle is often repeated 2-4 times per year (Guekht et al., 2011).
• Traumatic Brain Injury (TBI): High-dose therapy (50 mL IV daily) for 7-30 days is frequently recommended for moderate-to-severe injuries to improve long-term functional outcomes.
• Administration Safety: Doses up to 5 mL can be given intramuscularly (IM), while doses between 10-50 mL must be administered via slow IV infusion (diluted in 100-250 mL of saline) over 15-60 minutes to prevent dizziness or hot flashes.
• Supervision: Use must be strictly supervised by a healthcare professional, especially given its porcine origin and the need for sterile injection techniques.